Osteosarcoma is a type of bone cancer that primarily affects the long bones, such as those in the arms and legs, but it can also occur in other bones. It is most commonly diagnosed in adolescents and young adults, typically between the ages of 10 and 20, although it can occur at any age. By exploring the genetic landscape of Osteosarcoma, this research aimed to compile an extensive list of genes associated with Osteosarcoma, then identify the critical genes that drive this condition and to elucidate their significant roles in its progression. To achieve this, we collected Osteosarcoma-related genes by thoroughly reviewing the literature available on PubMed, specially selecting studies that showed a significant correlation between genes and Osteosarcoma (p-value < 0.05). In addition, we used databases such as My Cancer Genome Database, Cancer Genetics Web Database and osteosarcoma-db.uni-muenster.de. GeneMANIA (http://www.genemania.org) is a flexible, user-friendly web interface for generating hypotheses about gene function, analyzing gene lists and prioritizing genes for functional assays. Utilizing GeneMANIA Cytoscape software along with the CytoHubba plugin, we investigated the biological connections among these genes, visualizing a comprehensive network that highlights their interrelationships. Among all the osteosarcoma related genes collected, 168 genes were linked to drugs. These drugs included VX-702, Minocycline, MP470, Arsenic trioxide, Purvalanol, Flavopiridol, ABT-263, Olomoucine, SB-681323, SCIO-469. Among these drugs, Minocycline can affect ILB1-CYCS- CASP1- VEGFA-MMP9- CASP3- ALOX5 genes, Arsenic trioxide can affect MAPK1-MAPK3- JUN-AKT1- CCND1- IKBKB- TXNRD1 genes and VX-702 drug have a significant relationship with IL6-IL1B-TNF-MAPK14 genes and can affect these genes. This analysis not only allows us to identify crucial genes but also to discover the most important drugs associated with the genes related to Osteosarcoma, providing a better understanding of gene function. As a result, even in the later stages of our work, we can find non-coding RNAs associated with the top genes in Osteosarcoma and study their effects on these genes. This study could lead to the prescription of drugs that target non-coding RNAs, effectively silencing the genes that contribute to cancer progression.
